publication . Article . 2017

A New Noncanonical Anionic Peptide That Translocates a Cellular Blood–Brain Barrier Model

Sara Neves-Coelho; Rute P. Eleutério; Francisco J. Enguita; Vera Neves; Miguel A. R. B. Castanho;
Open Access English
  • Published: 01 Oct 2017 Journal: Molecules, volume 22, issue 10, page 1,753 (issn: 1420-3049, eissn: 1420-3049, Copyright policy)
  • Publisher: MDPI
Abstract
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). The capacity to transport therapeutic molecules across the blood–brain barrier (BBB) represents a breakthrough in the development of tools for the treatment of many central nervous system (CNS)-associated diseases. The BBB, while being protective against infectious agents, hinders the brain uptake of many drugs. Hence, finding safe shuttles able to overcome the BBB is of utmost importance. Herein, we identify a new BBB-trans...
Subjects
free text keywords: Blood–brain barrier, Organic chemistry, QD241-441, Drug-delivery systems, Communication, Cell-penetrating peptide, Anionic peptide
Funded by
EC| SIMICA
Project
SIMICA
Site-selective protein-modification chemistries for antibody-drug conjugates (ADCs)
  • Funder: European Commission (EC)
  • Project Code: 852985
  • Funding stream: H2020 | CSA
,
EC| SynaNet
Project
SynaNet
Neurologic and Psychiatric Disorders: from synapses to networks
  • Funder: European Commission (EC)
  • Project Code: 692340
  • Funding stream: H2020 | CSA
,
EC| INPACT
Project
INPACT
Innovative peptides against cancer and pathogenic bacteria, with advances in science, biopharmaceutical drug development, product market targeting, training , and communication.
  • Funder: European Commission (EC)
  • Project Code: 644167
  • Funding stream: H2020 | MSCA-RISE
,
FCT| SFRH/BPD/94466/2013
Project
SFRH/BPD/94466/2013
Peptides for blood-brain barrier transmigration and drug delivery ? novel therapies for the central nervous system (CNS)
  • Funder: Fundação para a Ciência e a Tecnologia, I.P. (FCT)
  • Project Code: SFRH/BPD/94466/2013
  • Funding stream: SFRH | Pós-Doutoramento
50 references, page 1 of 4

1. World Health Organization. Global burden of neurological disorders: Estimates and projections. In Neurological Disorders: Public Health Challenges, 1st ed.; Campanin, B., Ed.; World Health Organization: Geneva, Switzerland, 2006; pp. 32-33; ISBN 9241563362.

2. Neuwelt, E.; Abbott, N.; Abrey, L.; Banks, W.A.; Blakley, B.; Davis, T.; Engelhardt, B.; Grammas, P.; Nedergaard, M.; Nutt, J.; et al. Strategies to advance translational research into brain barriers. Lancet Neurol. 2008, 7, 84-96. [CrossRef]

3. Pardridge, W.M. The blood-brain barrier: Bottleneck in brain drug development. NeuroRx 2005, 2, 3-14. [CrossRef] [PubMed] [OpenAIRE]

4. Cummings, J.L.; Morstorf, T.; Zhong, K. Alzheimer's disease drug-development pipeline: Few candidates, frequent failures. Alzheimers Res. Ther. 2014, 6, 37. [CrossRef] [PubMed]

5. Obermeier, B.; Verma, A.; Ransohoff, R.M. The blood-brain barrier. Handb. Clin. Neurol. 2016, 133, 39-59. [PubMed] [OpenAIRE]

6. Ueno, M.; Chiba, Y.; Murakami, R.; Matsumoto, K.; Kawauchi, M.; Fujihara, R. Blood-brain barrier and blood-cerebrospinal fluid barrier in normal and pathological conditions. Brain Tumor Pathol. 2016, 33, 89-96. [CrossRef] [PubMed]

7. Kang, T.; Gao, X.; Chen, J. Harnessing the capacity of cell-penetrating peptides for drug delivery to the central nervous system. Curr. Pharm. Biotechnol. 2014, 15, 220-230. [CrossRef] [PubMed]

8. Gabathuler, R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol. Dis. 2010, 37, 48-57. [CrossRef] [PubMed]

9. Pardridge, W.M. Drug targeting to the brain. Pharm. Res. 2007, 24, 1733-1744. [CrossRef] [PubMed] [OpenAIRE]

10. Sanchez-Navarro, M.; Giralt, E.; Teixido, M. Blood-brain barrier peptide shuttles. Curr. Opin. Chem. Biol. 2017, 38, 134-140. [CrossRef] [PubMed]

11. de Figueiredo, I.R.; Freire, J.M.; Flores, L.; Veiga, A.S.; Castanho, M.A. Cell-penetrating peptides: A tool for effective delivery in gene-targeted therapies. IUBMB Life 2014, 66, 182-194. [CrossRef] [PubMed]

12. Kristensen, M.; Birch, D.; Morck Nielsen, H. Applications and Challenges for Use of Cell-Penetrating Peptides as Delivery Vectors for Peptide and Protein Cargos. Int. J. Mol. Sci. 2016, 17, 185. [CrossRef] [PubMed]

13. Mae, M.; Langel, U. Cell-penetrating peptides as vectors for peptide, protein and oligonucleotide delivery. Curr. Opin. Pharmacol. 2006, 6, 509-514. [CrossRef] [PubMed]

14. Jarver, P.; Mager, I.; Langel, U. In vivo biodistribution and efficacy of peptide mediated delivery. Trends Pharmacol. Sci. 2010, 31, 528-535. [CrossRef] [PubMed]

15. Egleton, R.D.; Davis, T.P. Bioavailability and transport of peptides and peptide drugs into the brain. Peptides 1997, 18, 1431-1439. [CrossRef]

50 references, page 1 of 4
Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue
publication . Article . 2017

A New Noncanonical Anionic Peptide That Translocates a Cellular Blood–Brain Barrier Model

Sara Neves-Coelho; Rute P. Eleutério; Francisco J. Enguita; Vera Neves; Miguel A. R. B. Castanho;